Unicycive Therapeutics earnings release, May 12, 2026

Unicycive Therapeutics, Inc. (UNCY) · Form 8-K, Item 2.02 · Filed · SEC filing

Unicycive

Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

MOUNTAIN

VIEW, Calif., May 12, 2026 --

Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the first quarter ended March 31, 2026, and provided a business update.

“As we approach the June 29th PDUFA target action date, we remain optimistic about the potential approval of OLC and focused on preparations for the subsequent launch of OLC,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “Our ongoing dialogue with the FDA during the review cycle has been constructive and timely. Uncontrolled hyperphosphatemia remains a significant health concern, affecting nearly 75% of U.S. patients with chronic kidney disease who are undergoing dialysis. OLC has the potential to improve adherence and phosphorus control with reduced pill burden, compared with currently available phosphate binders.”

Key

Highlights

& Upcoming Milestones

Financial

Results for the Quarter Ended March 31, 2026

As of May 11, 2026, un audited cash, cash equivalents, and marketable securities totaled $57.1 million. The Company believes that it has sufficient resources to fund planned operations into 2027.

Research and Development (R&D) expenses were $1.6 million for the quarter ended March 31, 2026, compared to $2.2 million for the three months ended March 31, 2025. The decrease in research and development expenses was primarily attributed to a decrease in drug development costs as well as consulting and professional fees.

General and Administrative (G&A) expenses were $6.8 million for the quarter ended March 31, 2026, compared to $5.8 million for the three months ended March 31, 2025. The increase was primarily attributed to an increase in consulting, professional services, and labor costs.

Other income (expense) was $(4.4) million expense for the quarter ended March 31, 2026, compared to $8.6 million income for the three months ended March 31, 2025, attributed primarily to an increase in the fair value of the Company’s warrant liability.

Net comprehensive income (loss) attributable to common stockholders, basic for the quarter ended March 31, 2026, was a $(12.8) million loss, or $(0.54) per share of common stock, compared to $0.5 million income, or $0.04 per share of common stock, for the three months ended

March 31, 2025. Net comprehensive income (loss) attributable to common stockholders, diluted for the quarter ended March 31, 2026, was a $(12.8) million loss, or $(0.54) per share of common stock, compared to a $(6.2) million loss, or $(0.50) per share of common stock, for the three months ended March 31, 2025. The increased net loss for the quarter ended March 31, 2026, was attributed primarily to an increase in the fair value of the Company’s warrant liability.

About Unicycive

Therapeutics

Unicycive

Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation

(ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.

Financial statements

Balance Sheet

As of December 31, 2025 — (In thousands, except for share and per share amounts)

As of December 31, 2025As of March 31, 2026 – (Unaudited)
Current assets:Cash and cash equivalents29,19837,371
Current assets:Prepaid expenses and other current assets7,6928,959
Current assets:Marketable securities12,07117,215
Current assets:Total current assets48,96163,545
Current assets:Right of use asset, net108813
Current assets:Property and equipment, net6648
Current assets:Total Assets49,13564,406
Current liabilities:Accounts payable3831,140
Current liabilities:Accrued liabilities1,5233,052
Current liabilities:Warrant liability16,91521,695
Current liabilities:Operating lease liability – current117598
Current liabilities:Total current liabilities18,93826,485
Current liabilities:Operating lease liability – long term217
Current liabilities:Total Liabilities18,93826,702
Stockholders’ Equity:Common stock, $0.001 par value per share – 400,000,000 shares authorized at December 31, 2025, and March 31, 2026; 22,114,245 and 25,237,782 shares issued and outstanding at December 31, 2025, and March 31, 2026, respectively2225
Stockholders’ Equity:Accumulated other comprehensive (loss) income-16
Stockholders’ Equity:Additional paid-in capital158,001178,321
Stockholders’ Equity:Accumulated deficit-127,825-140,648
Stockholders’ Equity:Total Stockholders’ Equity30,19737,704
Stockholders’ Equity:Total Liabilities And Stockholders’ Equity49,13564,406
Full release

Forward-looking statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.

These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions.

These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; our dependence on third parties for manufacturing; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; market acceptance of our products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled

‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new... (truncated)vents or otherwise.

Investor

Contacts:

Kevin

Gardner

LifeSci Advisors kgardner@lifesciadvisors.com

Media

Contact:

Layne

Litsinger

Real Chemistry llitsinger@realchemistry.com

SOURCE: Unicycive

Therapeutics, Inc.²

Unicycive

Therapeutics, Inc.

BALANCE

SHEETS

(In thousands, except for share and per share amounts)³

Unicycive

Therapeutics, Inc.

Statements of Operations and Comprehensive Income (Loss)

(In thousands, except for share and per share amounts)

(Unaudited)⁴

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Unicycive Therapeutics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.